Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic testing may benefit people receiving low-dose lithium in clinical practice.

Journal of the American Association of Nurse Practitioners - 1 Jun 2024

Dickerson Michael Ray, Reed Jennifer

Abstract excerpt

BACKGROUND: Mental illnesses are leading causes of disability in the United States. Some evidence supports that pharmacogenetic testing may be beneficial in select populations and that lithium is beneficial for treating mood disorders and anxiety in some populations. PURPOSE: This research aimed to determine whether low-dose lithium effectively decreases depression and anxiety in adults with a risk allele for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Anxiety
Share to Bipolar Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calcium Channels, L-Type

Share to Lithium

Share to Pharmacogenomic Testing

Share to Polymorphism, Single Nucleotide

Share to Surveys and Questionnaires

Source

Identifiers

PMID: 37882688
DOI: 10.1097/JXX.0000000000000968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic testing may benefit people receiving low-dose lithium in clinical practice.PMID 37882688Read ↗

Lithium response in bipolar disorder: Genetics, genomics, and beyondSemantic proximity Read ↗

Evidence for the impact of the CACNA1C risk allele rs1006737 on 2-year cognitive functioning in bipolar disorder.Semantic proximity Read ↗

Pharmacogenetics of lithium response: close to clinical practice?Semantic proximity Read ↗

Need exists for genetic predictors of lithium response.Semantic proximity Read ↗

Molecular actions and clinical pharmacogenetics of lithium therapySemantic proximity Read ↗

The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia.Semantic proximity Read ↗

CACNA1C polymorphisms Impact Cognitive Recovery in Patients with Bipolar Disorder in a Six-week Open-label Trial.Semantic proximity Read ↗

Patients' Perspectives on Psychiatric Pharmacogenetic Testing.Semantic proximity Read ↗

Genetic polymorphisms influencing response to lithium in early-onset Bipolar disorder from south India.Semantic proximity Read ↗

Prediction of lithium response using genomic data.Semantic proximity Read ↗

Lithium response and genetics of affective disordersSemantic proximity Read ↗

Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.